NCT04701307 2026-04-22
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT03830918 2026-02-12
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT05718323 2026-02-06
RAISE
ETOP IBCSG Partners Foundation
Phase 2 Recruiting
NCT04475939 2026-01-08
ZEAL-1L
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT05455424 2025-05-15
NERO
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT04940637 2023-05-12
UNITO-001
University of Turin, Italy
Phase 2 Unknown
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT05162196 2022-05-02
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Phase 2 Unknown
NCT03221400 2022-02-17
PEN-866 in Patients With Advanced Solid Malignancies
Tarveda Therapeutics
Phase 1/2 Unknown
NCT03891615 2020-12-16
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
Massachusetts General Hospital
Phase 1 Unknown